Suppr超能文献

I-mIBG 心脏/纵隔比值的可靠性:多中心测试-再测试可重复性研究的结果。

Reliability of the I-mIBG heart/mediastinum ratio: Results of a multicenter test-retest reproducibility study.

机构信息

Mid America Heart Institute, 4320 Wornall Road, Suite 2000, Kansas City, MO, USA.

Henry Ford Hospital, Detroit, MI, USA.

出版信息

J Nucl Cardiol. 2019 Oct;26(5):1555-1565. doi: 10.1007/s12350-017-1183-6. Epub 2018 Jan 17.

Abstract

A quantitative measurement, the Heart-to-Mediastinum (H/M) ratio of counts derived from a planar acquisition approximately 4 hours after injection of I-mIBG, is a strong predictor of outcomes in patients with stable class II-III heart failure and LVEF ≤ 35%. This study assessed the test-retest reproducibility of the H/M ratio in such patients. 47 subjects with class II-III systolic heart failure and LVEF ≤ 35% were tested at two time intervals separated by 5 to 14 days. Subjects were imaged twice on the same camera using the same radionuclide dose. Images were sent to a core analysis lab, where three nuclear technologists independently determined the H/M ratios. The primary endpoint was test-retest H/M ratio reproducibility calculated as the absolute difference in mean value determined by the three readers. Mean subject age was 65 ± 12 years, 85% were male, and mean BMI was 29 ± 6 kg/m. Mean injected activity was 10.18 ± 0.43 mCi for first dose and 10.09 ± 0.52 mCi for the second dose. The mean and SD values for first and repeat studies were almost identical: the 95% confidence interval of the mean test-retest difference was 0.055 to 0.076. Bland-Altman plots showed no systematic effect of the H/M ratio on the magnitude of the difference between replicate measurements. Inter-reader measurements were nearly identical. There were no serious adverse events despite exposure to I-mIBG on 2 occasions in a short time period. The Heart-to-Mediastinum ratio of I-mIBG is a consistent and highly reproducible measurement in stable Class II to III heart failure patients.

摘要

心-纵隔(H/M)比值是一种定量测量指标,通过注射碘-间位碘苄胍(I-mIBG)后约 4 小时进行平面采集获得。该比值是心功能 II-III 级且左心室射血分数(LVEF)≤35%的稳定心力衰竭患者结局的强有力预测指标。本研究评估了该比值在这类患者中的测试-重测可重复性。47 名心功能 II-III 级且 LVEF≤35%的收缩性心力衰竭患者在相隔 5-14 天的两个时间点接受了两次检查。所有患者均在同一台相机上使用相同的放射性核素剂量进行了两次成像。将图像发送至核心分析实验室,由 3 名核技术人员独立确定 H/M 比值。主要终点是由 3 位读者确定的平均 H/M 比值的测试-重测可重复性,计算方法为 3 位读者的平均值之间的绝对值差异。患者平均年龄为 65±12 岁,85%为男性,平均 BMI 为 29±6kg/m。首剂量和第二剂量的平均注射活度分别为 10.18±0.43mCi 和 10.09±0.52mCi。首次和重复研究的均值和标准差几乎相同:平均测试-重测差值的 95%置信区间为 0.055 至 0.076。Bland-Altman 图显示 H/M 比值对重复测量之间差值的大小无系统影响。读者间的测量值几乎相同。尽管在短时间内两次接触 I-mIBG,但没有发生严重不良事件。在稳定的心功能 II-III 级心力衰竭患者中,碘-间位碘苄胍的 H/M 比值是一种一致且高度可重复的测量指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验